On October 5, 2026 Iambic Therapeutics, Inc. (Iambic), a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, reported the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 clinical trial evaluating IAM217, a brain-penetrant, differentiated inhibitor of KIF18A for the potential treatment of triple-negative breast cancer, ovarian cancer, and other solid tumor indications with chromosomal instability (CIN). In a preclinical brain metastasis model, IAM217 produced approximately 90% regression of established intracranial tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Iambic’s mission is to make better technology for better medicines, and today marks another important milestone for the company," said Tom Miller, PhD, Co-Founder and CEO, Iambic. "With IAM217 poised to enter clinical trials, IAM1363 well underway in clinical trials, and our CDK2/4 dual inhibitor program advancing toward IND submission, we believe that we are seeing meaningful productivity from our molecular superintelligence platform."

KIF18A is a mitotic motor protein (kinesin) that governs chromosome alignment during cell division. Cancer cells with CIN — a hallmark of many of the most aggressive and treatment-refractory cancers — depend on KIF18A to complete cell division, while normal cells tolerate its inhibition, creating a potential therapeutic window distinct from broadly cytotoxic antimitotic agents. There is emerging clinical evidence that potentially validates KIF18A as an important target for high-grade serous ovarian cancer and preclinical evidence for a variety of other malignancies, including triple-negative breast cancer.

IAM217 is a product of Iambic’s AI-driven, molecular superintelligence platform. Iambic designed IAM217 without access to a high-resolution co-crystal structure of KIF18A bound to an inhibitor. NeuralPLexer was instead leveraged to supply structural insights. The allosteric binding mode confers mechanistic selectivity over other kinesin family members and avoids the cytotoxic liabilities associated with tubulin-targeting mitotic agents. Enchant and earlier Iambic property-prediction AI tools were then deployed for large-scale multi-parameter optimization. From an initial set of 100 nM-class hits identified in 24 high-throughput experimentation plates, AI-guided design drove potency improvement to multiple 10 nM-class compounds while simultaneously optimizing oral bioavailability, reducing CYP-mediated drug-drug interaction liabilities, and engineering CNS penetrance. At the stage of lead identification, brain penetrance was achieved within approximately six months.

"We believe IAM217 has the potential to be a differentiated inhibitor for cancers that rely on KIF18A to proliferate," said Pete Olson, PhD, Chief Scientific Officer, Iambic. "With IAM217, we see the opportunity for strong anti-tumor activity in patients with brain metastases, supported by a biomarker-informed development strategy. This investigational medicine could not have been nominated without our AI-driven platform, allowing us to optimize for key properties and quickly move through IND-enabling studies."

Subject to FDA clearance of the IND, IAM217 will become Iambic’s second program to enter clinical trials. Iambic is also advancing IAM1363, a highly selective and brain-penetrant HER2 inhibitor, in an ongoing Phase 1/1b clinical trial, and anticipates submitting an IND for IAM-C1, its CDK2/4 dual inhibitor, later in the fourth quarter of 2026, and subject to FDA clearance of the IND, to initiate a Phase 1/2 trial.

(Press release, Iambic Therapeutics, OCT 5, 2026, View Source [SID1234673199])

On October 5, 2026 Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AFT-70 NAVIGATE is designed to test whether patients can maintain excellent outcomes while more selectively using CDK4/6 inhibitors, rather than exposing all patients to prolonged combination therapy. The strategy pairs giredestrant, an investigational highly active next-generation oral selective estrogen receptor degrader (SERD), with longitudinal Signatera Genome MRD monitoring, to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.

Giredestrant was selected as the endocrine therapy backbone for the investigational arm based on results from the phase III lidERA trial, which showed giredestrant achieved a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine monotherapy in patients with ER-positive/HER2-negative early breast cancer. These findings support the potential for giredestrant to provide an endocrine therapy backbone on which an MRD-guided treatment strategy can be built.

Signatera was selected as the MRD test for this trial based on its extensive clinical evidence in ER-positive, HER2-negative early breast cancer, including from the AFT-05 PALLAS and MonarchE trials, and because of its new ultrasensitive Genome-based technology with Phased and Structural Variants reporting analytical sensitivity below 1 ppm (parts per million).

AFT expects to enroll more than 2,000 patients with stage II-III ER-positive/HER2-negative breast cancer who are eligible for endocrine therapy at approximately 200 sites across the U.S. and internationally. Patients with no detectable MRD by Signatera after completing standard-of-care treatment, including surgery, radiotherapy, and chemotherapy when indicated, will be randomly assigned to one of two approaches: (1) a control arm receiving standard-of-care endocrine therapy plus upfront CDK4/6 inhibition; or (2) an investigational arm receiving giredestrant monotherapy, with CDK4/6 inhibition added only if Signatera becomes positive. The primary endpoint is non-inferiority in 4-year distant recurrence-free survival.

"This collaboration brings together leading expertise in breast cancer research, clinical care, and molecular testing to address an important question for patients: How can we make treatment more precise while avoiding unnecessary toxicity?" said Evanthia Galanis, M.D., D.Sc., president of Alliance Foundation Trials, LLC. "By using MRD technology to guide treatment decisions, this trial has the potential to transform care for eligible breast cancer patients and individualize treatment intensity."

"We know that patients with ER-positive, HER2-negative breast cancer do not all face the same risk of recurrence, yet adjuvant treatment decisions are still largely based on clinical and pathological features measured at diagnosis," said Komal Jhaveri, M.D., FACP, FASCO study chair, breast medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center. "The AFT-70 NAVIGATE trial combines two important advances: an endocrine therapy backbone with giredestrant and longitudinal MRD testing with Signatera that can provide a dynamic measure of recurrence risk. The trial will determine whether MRD-guided monitoring can distinguish patients most likely to benefit from adding a CDK4/6 inhibitor from those in whom it can be safely omitted. It’s an important step forward using biology—not just baseline risk—to guide adjuvant therapy."

"More treatment is not always better treatment," said Gaorav Gupta, M.D., Ph.D., study co-chair, breast radiation oncologist, and co-leader of the Breast Cancer Research Program at UNC Lineberger Comprehensive Cancer Center. "CDK4/6 inhibitors can be an important part of care for some patients, but they can also add side effects, monitoring, and treatment burden. If highly sensitive blood-based MRD testing can identify patients who can safely defer additional therapy, we may be able to spare many patients from the burdens of more treatment while maintaining excellent cancer control. That is the promise we hope to explore through this study."

"Natera and AFT have a longstanding partnership and shared commitment to cutting-edge trials across many cancer types," said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera. "AFT-70 NAVIGATE creates enormous potential to enhance treatment options for patients with intermediate and high-risk, hormone receptor positive breast cancer."

(Press release, Genentech, OCT 5, 2026, View Source [SID1234673198])

On October 5, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported Cancer Research Communications, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients with resected stage II–III melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The COSMOS (COnquer Solid Malignancies by blOod Screening) program is a large prospective initiative evaluating MRD detection with the Guardant Reveal test across six cancer types. This report presents findings from COSMOS-MEL01, in which 280 longitudinal surveillance samples from 48 patients with clinical stage II–III melanoma treated with surgery were analyzed. The study found that detection of circulating tumor DNA (ctDNA) following surgery was strongly associated with recurrence and melanoma-related death. During longitudinal surveillance, Guardant Reveal detected 81% of distant recurrences, with 100% specificity in post-treatment samples from patients who remained recurrence-free. ctDNA detection preceded clinical identification of recurrence by a median of 70.5 days. These findings support the use of Guardant Reveal as a rapid, noninvasive approach for earlier identification of patients at high risk for recurrence, enabling refined treatment and surveillance strategies.

"Patients with resected, high-risk melanoma need more precise tools to assess how their risk changes after surgery and throughout surveillance," said Yoshiaki Nakamura, M.D., Ph.D., former Chief, International Research Promotion Office at National Cancer Center Hospital East in Chiba, Japan, and a co-lead author of the study. "These results show that ctDNA detection using a tissue-free assay was associated with a substantially increased risk of recurrence and melanoma-related death and often preceded clinical detection of disease. Fast, broadly accessible testing would be valuable in helping to inform therapy for patients with substantially higher risk of melanoma recurrence and poorer survival than those who remained ctDNA-negative."

"Predicting melanoma recurrence after surgery remains difficult at the individual-patient level, and conventional clinicopathologic staging provides only a static estimate of risk," said Kenjiro Namikawa, M.D., Ph.D., Chief, Department of Dermatologic Oncology at National Cancer Center Hospital in Tokyo, Japan. "Our findings suggest that serial ctDNA testing may provide a dynamic view of recurrence risk and potentially complement routine imaging, particularly in identifying patients at increased risk of distant relapse. Further studies will be important to determine whether and how ctDNA results could be incorporated into postoperative treatment and surveillance decisions."

Key study findings include:

100% specificity in samples from patients without recurrence
81% longitudinal sensitivity for distant recurrence detection
Up to 273-day lead from ctDNA detection to recurrence
"COSMOS-MEL01 extends the growing body of evidence supporting Guardant Reveal into melanoma and demonstrates the power of epigenomic MRD detection across a diverse set of melanoma subtypes," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "The ability to identify patients at very high risk shortly after surgery, and to detect molecular recurrence before it appears clinically, could help inform more personalized surveillance and clinical trial strategies. These findings also illustrate the advantages of a tissue-free approach that can deliver molecular insights without the logistical complexity of obtaining and analyzing a tumor specimen."

The incidence of melanoma is steadily rising, with annual cases projected to increase by more than 50% between 2020 and 2040. The COSMOS study provides strong evidence for the use of Guardant Reveal to improve recurrence risk stratification to inform management decisions for this significantly large patient population.

The study was published today at 10 a.m. EDT in Cancer Research Communications.

About Guardant Reveal

Guardant Reveal is a tissue-free liquid biopsy test that detects MRD and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.

The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.

(Press release, Guardant Health, OCT 5, 2026, View Source [SID1234673197])

On October 5, 2026 BlueWhale Bio, Inc., a company dedicated to transforming immune cell therapy manufacturing, reported a series of updates demonstrating continued progress across its Synecta platform. Items include new clinical and functional data supporting Synecta-manufactured CAR-T cells, the launch of Synecta T1 Enhanced to enable clinical development and expanded distribution in China and Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re encouraged by the emerging clinical and functional evidence supporting our technology and seeing that progress translate into broader clinical use and access," said Peter Keller, Chief Executive Officer of BlueWhale Bio. "With Synecta grade available to support clinical development and new distribution in China and Europe, we’re building the foundation to enable more cell therapy developers to incorporate our technology into their clinical programs."

New Data Support Synecta-Manufactured CAR-T Cells

At the University of Pennsylvania, preliminary follow-up from refractory lymphoma and leukemia patients receiving Synecta-manufactured huCART19-IL18 showed measurable CAR-T exposure in all four patients at Day 100, with persistence observed through one year (more than twice as long as observed in four patients from a prior dose-matched lymphoma cohort whose CAR-T cells were manufactured using conventional bead-based activation). Three of the four patients receiving Synecta-manufactured cells achieved durable complete responses.

Building on these persistency observations, a team at Children’s Hospital of Philadelphia (CHOP) is preparing to use Synecta T1 to manufacture CAR-T cells for a study in children with relapsed acute lymphoblastic leukemia, with the goal of evaluating whether the approach could reduce the need for subsequent bone marrow transplantation.

"Synecta has delivered strong activation and high-quality cells, giving us confidence as we plan its use in a challenging population," said Stephan Kadauke, MD, PhD, Associate Director of CHOP’s Cell-Based Therapy Laboratory.

Complementing these clinical observations, single-cell imaging conducted with Applied Cells, Inc. using Celldom, Inc.’s CloneXplorer platform showed that Synecta manufacturing yielded a greater proportion of CAR-T cells capable of both serial tumor-cell killing and subsequent proliferation compared with bead-based manufacturing.

Synecta T1 Enhanced Launch Supports Bench-to-Bed Translation

BlueWhale Bio has launched Synecta T1 Enhanced, a product grade that can support the use of cell-derived nanoparticles in clinical-stage cell therapy programs. Synecta T1 Enhanced is supported by quality documentation filed in BlueWhale’s FDA Drug Master File.

BlueWhale Bio Expands Synecta Access in China and Europe

In parallel with its clinical development activities, BlueWhale Bio is expanding access to Synecta internationally. The company has appointed MineBio and Tebubio to distribute Synecta in China and Europe, respectively, providing customers in these regions with local product access and scientific support.

BlueWhale Bio to Present at Cell & Gene Meeting on the Mesa

Peter Keller will provide an update on the company’s business and development strategy at the Cell & Gene Meeting on the Mesa in Phoenix, AZ, on Tuesday, October 6, 2026, at 3:00 pm MST in FLW Ballroom G.

(Press release, BlueWhale Bio, OCT 5, 2026, View Source [SID1234673196])

On October 5, 2026 Pillar Biosciences reported the launch of the oncoReveal Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies. The panel expands the original oncoReveal Myeloid Panel from 58 to 80 gene targets and enhances detection of FLT3 internal tandem duplications (ITDs), including long and multiple ITDs that can be challenging for NGS assays.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Building on the original 58-gene panel, oncoReveal Myeloid v2 adds 22 genes while retaining all prior content, giving laboratories broader, guideline-relevant coverage without disrupting existing workflows. Only 4 out of the original 766 amplicons covering the original 58 genes are changed to accommodate the expansion — a result of Pillar’s proprietary SLIMamp chemistry and VersaTile primer design tool, which together enable efficient panel scaling while preserving the validated performance of existing content. The full updated gene list will be available on pillarbiosci.com at launch.

"With oncoReveal Myeloid v2, we significantly expanded our myeloid gene content while preserving the trusted panel content laboratories already rely on," said ShiPing Zou, Senior Director, Product Management at Pillar Biosciences. "We also invested significant effort in FLT3-ITD detection so laboratories can obtain accurate, base-pair-resolved calls for long and multiple ITDs without defaulting to a separate fragment-analysis workflow."

A key advancement in oncoReveal Myeloid v2 is the ability to accurately detect long (300+ bp) and multiple FLT3 internal tandem duplications (ITDs) with 2 x 150 sequencing, a variant class that has historically challenged short-read NGS:

Why FLT3-ITDs are challenging

FLT3-ITDs occur in an estimated 20–30% of de novo AML cases and are associated with poor prognosis, making accurate detection important to the profiling of heme malignancies.
ITDs can range from a few base pairs to more than 400 bp. Their repetitive sequence content can make it difficult for short-read NGS panels to detect and size accurately, particularly longer ITDs.
Laboratories have therefore historically relied on capillary electrophoresis (CE) fragment analysis to confirm FLT3-ITD status and calculate allelic ratio (AR), adding time and complexity.
Performance with long and multiple ITDs

In an independent evaluation of 111 myeloid/MPN samples, including 23 FLT3-ITD-positive samples with ITDs from 12 bp to 279 bp, the oncoReveal Myeloid v2 Panel and PiVAT informatics accurately detected and sized ITDs using standard 2×150 bp short-read sequencing. This included ITDs up to 279 bp and 9 samples with 2–4 concurrent ITDs.
Detection of long and multiple ITDs in a single NGS run can identify distinct clonal populations, each with its own ITD length and variant allele frequency (VAF), within the same sample—detail that a single CE-based allelic ratio can obscure.
NGS-derived VAFs trended consistently with allelic ratios from orthogonal CE-based fragment analysis across evaluated ITD lengths, supporting confidence in the NGS-based calls.
FLT3-ITDs were detected to ≤1% VAF, providing researchers with a sensitive, single-workflow alternative to routing FLT3-suspected samples to separate fragment analysis.

(Press release, Pillar Biosciences, OCT 5, 2026, View Source [SID1234673195])